We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Proteome Sciences Plc | PRM | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.05 | 1.47% | 3.45 | 16:35:23 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 3.45 | 3.40 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 22/7/2024 12:27 by sandcrab2 The excellent Fgnoms covered this 13 years ago“fgnoms30 Apr '11 - 10:28 - 14 of 26 0 0 0 Well here we are at the end of April and still no commercial money-making contracts have been signed. CJP at the time of the money raising reiterated break even for 2010, which would have required a few such contracts to have been signed in say late Q3 2010. So seven months on and NO such deals have been signed. I guess the important question is why? Of course we have suffered the same sorry story for the last 4 years on stroke. Yes 4 years ago contracts were imminent and apparently still are but we haven't been told why they haven't been signed. The obvious explanation is that PRM stroke biomarkers together with other panel constituents don't work well enough and therefore a stroke panel cannot be commercialised. Remember all those companies testing the PRM stroke biomarkers - and absolutely nothing has resulted. I think it would now be reasonable to assume that stroke is dead. So what about AD. Yes we are now at the same stage as stroke was 4 years ago. Tests are being carried out - but this time by PRM itself. This indicates to me that none of the big boys have any faith whatsoever in PRM's AD biomarkers - especially since the Dutch revelation that Clusterin isn't a predictive biomarker. So why does PRM continue to lead us on that a commercial deal is just around the corner. I find this bizarre. As PRM is now carrying out its own tests on its own panel nobody is going to sign anything until the results are known - which will probably be in H1 2012. And even then it really isn't feasible that a final saleable AD working panel will only contain PRM biomarkers, is it? So in my view we are years away from a working AD panel. So where does all this optimism come from - cloud cuckoo land imho. So before my next post we will know the 2010 results - a complete disaster no doubt. A loss of nearly £5m compared with target breakeven. 2011 is also looking like another £5m loss as I don't believe any commercial contracts will be signed. 2012 may not be much better either and thats when the cash runs out. So what will the share price be when all this is revealed next month? A very far cry from anything the rampers are saying thats for sure.” |
Posted at 25/6/2024 09:00 by monte1 ‘Sooner’ - that term and PRM are exceedingly unlikely bedfellows. |
Posted at 25/6/2024 08:06 by wasjobber Joeblogg2,That's your choice, but in my opinion this is going to fly soon. PRM are in an excellent position and might be taken over sooner than many people think. |
Posted at 19/6/2024 10:45 by monte1 Further insight into latest PRM business plan;Commercial In Confidence ‘Let’s just Wait and See’ Ends. |
Posted at 19/6/2024 07:37 by goatherd peverill,You do not seem to understand PRM's tactics. They have a large number of patents. They are simply watching other people testing and using them for reaearch (for which a license is not required). Then when (and if :-( ) they start to use them clinically, they will step in and demand royalties. Of course they will not want to alert users too early, as the user might find different, non-PRM-patented, biomarkers; but if they wait until the user is heavily commited it should work. |
Posted at 19/6/2024 07:05 by peverill Is any of the Patent portfolio any good,Parkinson's test successful in early stage testing,I am taking it no biomarkers from PRM included,another opportunity missed.!! |
Posted at 14/6/2024 23:46 by goggin https://x.com/busine |
Posted at 07/6/2024 19:09 by goggin Keep an eye on Bird flu, don't know if PRM has anything in that line |
Posted at 10/4/2024 10:02 by pools2 wasjobber,Thermo have been a long term partner of Proteome Sciences for 15 years, but I agree it'll be good to see Thermo taking a more prominent position. After reading the RNS this morning, the future looks brighter than ever. You've already mentioned what I think is probably the most significant RNS statement:- "It's very interesting that PRM are now openly stating that their patented Alzheimer's and cancer biomarkers may be critical to new diagnostics and treatment moving forward. STRONG BUY" It's very significant for Proteome Sciences to say that. The value of these biomarkers will be considerable and will project PRM into the £100 millions plus market cap. with ease. I think you are now correct, we are at a pivotal moment for the share price and investors buying now will achieve significant returns, possibly quicker than some may think. |
Posted at 05/4/2024 07:25 by peverill Are pools and wasjobber one and the same.They have a knack of both putting 2+2 together to make 5.Where anywhere does it say the NHS are using PRM markers in these trials,Given PRM's precarious position you would think they would be shouting from the rooftops if true. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
